Skip to content
Sign in
OtherBacked 1 network startup

Dara Holdings

Holding that invested in BioSapien's US$5.5M pre-Series A (oncology drug delivery); profile is undocumented.

Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
1most often with Global Ventures

How they invest

Unknown; one deal: BioSapien (MediChip, localized cancer drug delivery, UAE trials).

Stage and ticket

Unknown; pre-Series A participation.

Geography

Unknown.

What makes them say yes

  • Inferred: clinical-stage biotech
  • Inferred: UAE link
  • Unknown

Red flags

  • Unknown
  • Unknown

Sectors

Not published

Stages

Not published

Geographies

Not published

How to approach

Ask BioSapien's founders for an intro.

Portfolio

1 network startup · no other company

One network deal (BioSapien, Dec 2024).

Gaps in the portfolio

  • Profile undocumented

Network startups

  • BioSapienSWC 2026 Top 10

    3D-printed biodegradable MediChip implant delivering chemotherapy locally at the tumour site, now in colorectal cancer trials in the UAE.

    United Arab Emirates · Biotech & life sciences

    • pre-Series A · $5.5M · 1 Dec 2024Source

Network startups that fit

3 analysed

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

Korean acute-kidney-injury drug in phase 2a: clinical-stage biotech like BioSapien.

20%confidence

Evidence from the records

  • “Drug for acute kidney injury”
  • “phase 2a under way in Korea”
Intro path
BioSapien (Dara portfolio)
First step
Ask BioSapien for an intro.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Global Ventures

Sources

  1. 1wamda.com/2024/12/uae-based-biotech-biosapien-secures-5-5-million-pre

Profile compiled from public sources. Unknown fields are left empty rather than estimated.